cancer

When FDA Requires Pediatric Studies for New Cancer Drug Submissions: New Draft Guidance
When FDA Requires Pediatric Studies for New Cancer Drug Submissions: New Draft Guidance
RAPS.org
FDA
cancer
oncology
pediatric cancer
pediatric
Flag link:
Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo
Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo
Pharmaceutical Business Review
Vedanta Biosciences
VE800
Bristol-Myers Squibb
Opdivo
cancer
clinical trials
Flag link:
AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis
AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis
BioSpace
AbbVie
Scripps Research Institute
cancer
immunology
fibrosis
Flag link:
ASH19: AZ’s Calquence throws gauntlet down to Imbruvica
ASH19: AZ’s Calquence throws gauntlet down to Imbruvica
Pharmaforum
AstraZeneca
cancer
Calquence
ASH2019
Imbruvica
JNJ
AbbVie
CLL
Flag link:
Why The Obsession With A Universal Cure For Cancer May Be Harming Research And Patients
Why The Obsession With A Universal Cure For Cancer May Be Harming Research And Patients
Forbes
cancer
oncology
R&D
universal cancer vaccine
Flag link:
Lilly puts its cancer future in Loxo's hands
Lilly puts its cancer future in Loxo's hands
Biopharma Dive
Eli Lilly
Loxo Oncology
M&A
cancer
R&D
oncology
Flag link:
How a New Method is Improving Whole Genome Sequencing of FFPE Tumor Tissues
How a New Method is Improving Whole Genome Sequencing of FFPE Tumor Tissues
Xtalks
cancer
R&D
FFPE
genome sequencing
Flag link:
Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio
Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio
Fierce Pharma
Roche
Mylan
Herceptin
biosimilar
cancer
oncology
Ogivri
Flag link:
Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test
Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test
Endpoints
MaxiVAX
cancer
vaccines
cancer vaccines
solid tumors
head and neck cancer
Flag link:
Teva forms academic R&D pacts to further biopharma strategy
Teva forms academic R&D pacts to further biopharma strategy
Fierce Biotech
Teva Pharmaceutical
Israel
cancer
oncology
R&D
Flag link:
2 Small-Cap Biotechs That Soared Last Week
2 Small-Cap Biotechs That Soared Last Week
Motley Fool
Magenta Therapeutics
Molecular Templates
gene therapy
CAR-T
cancer
Flag link:
AstraZeneca CEO: Closing In On A Cancer Cure
AstraZeneca CEO: Closing In On A Cancer Cure
Yahoo/Benzinga
AstraZeneca
Pascal Soriot
oncology
cancer
Flag link:
With Cell-By-Cell Take on Drug Discovery, Immunitas Debuts With $39M
With Cell-By-Cell Take on Drug Discovery, Immunitas Debuts With $39M
Xconomy
Immunitas Therapeutics
single-cell genomics
cancer
drug discovery
Flag link:
AstraZeneca, Merck win red carpet treatment at the FDA as a 3-time loser seeks speedy OK for rare tumors
AstraZeneca, Merck win red carpet treatment at the FDA as a 3-time loser seeks speedy OK for rare tumors
Endpoints
AstraZeneca
Merck
selumetinib
cancer
Flag link:
Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors
Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors
Fierce Biotech
Bolt Biotherapeutics
immuno-oncology
clinical trials
cancer
Flag link:
First use of CRISPR against cancer in patients clears early safety hurdles
First use of CRISPR against cancer in patients clears early safety hurdles
Stat
gene editing
CRISPR
patient safety
cancer
Flag link:
Radius plans to cut loose oncology assets
Radius plans to cut loose oncology assets
Fierce Biotech
Radius
oncology
cancer
endocrine disorders
osteoporosis
Flag link:
A2 Biotherapeutics emerges from stealth mode to develop tumour cell therapeutics
A2 Biotherapeutics emerges from stealth mode to develop tumour cell therapeutics
Pharmaceutical Business Review
A2 Biotherapeutics
cell therapy
cancer
Flag link:
It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster
It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster
Endpoints
Novartis
FDA
Amgen
Neulasta
biosimilars
Ziextenzo
cancer
Flag link:
CMS proposes lifting restrictions on NGS cancer testing
CMS proposes lifting restrictions on NGS cancer testing
Biopharma Dive
CMS
next generation sequencing
diagnostics
oncology
cancer
Medicare
Flag link:

Pages